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Abstract: A novel galactosylated cholesterol with mono-galactoside moiety, (5-cholesten-3-yl)- 
4-oxo-4-[2-(lactobionylamido)ethylamido]butanoate 6 was synthesized.  Its chemical structure 
was characterized by IR, ESI-MS, 13C NMR, 1H NMR.  Doxorubicin entrapped in the liposomes 
containing 10% mol/mol 6 was rapidly accumulated in liver and mainly uptake by parenchymal 
cells in mice. 
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Mammalian hepatocytes (parenchymal cells) exclusively possess large number of 
asialoglycoprotein receptors (ASGPr), which can recognize terminal D-galactose or 
N-acetylgalactosamine residues.  Lactobionic acid 1, bearing a galactosyl group, is 
usually used as a recognizing moiety of the hepatocyte-targeting carrier1.  Cholesterol, 
one of the lipid components used to form liposomes, is usually selected as the lipophilic 
anchor moiety for stably introducing the galactosyl moiety in liposomes2,3.  In the 
present study, 1 and cholesterol were chemically attached via the esterification and 
amidation reactions to form a novel galactosylated cholesterol (Scheme 1), (5-cholesten- 
3β-yl)4-oxo-4-[2-(lactobionylamido)ethylamido]butanoate 6, which had a great potential 




A solution of lactobionic acid calcium salt was passed through a cation-exchange resin 
column (Dowex 50WX8) to convert to free lactobionic acid 1.  The eluted free acid 
solution was lyophilized and converted to lactobionic lactone 2 by repeated evaporation 
from methanol and ethanol4. 
A solution of 2 (5 g, 14.7 mmol) in 50 mL methanol was added dropwise to the 
solution of ethylenediamine (8.8 g, 147 mmol) in 20 mL methanol.  The reaction 
mixture was stirred at reflux for 6 h, then the solvent was removed.  300 mL dichloro- 
methane was added to the residue and the precipitated white crystals were filtered and 
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washed with ether and small amount of cold methanol, yielding 5.03 g (12.6 mmol, 
85.7%) of 1-N-[O-β-D-galactopyranosyl-(1,4)-D-gluconamide]-2-N'-methylamine 3. 
N-Hydroxysuccinimidyl 5-cholesten-3β-yloxy succinate 4 was synthesized accor- 
ding to the method previously described by Kempen et al.5.  Briefly, cholesterol (3.87 g, 
10 mmol) was dissolved in 20 mL dichloromethane and 5 mL pyridine, and then succinic 
anhydride (1.03 g, 10 mmol) was added.  After stirring at reflux for 8 h, the mixture 
was evaporated to dryness.  The residue was dissolved in warm acetone and crystallized 
by cooling to -20°C overnight to yield 4.05 g (8.32 mmol, 83.2%) of cholesteryl 
hydrogen succinate 4.  And then, N, N'-dicyclohexylcarbodiimide (5 g, 24.2 mmol) was 
added to the mixture of the solution of 4 (4.0 g, 8.2 mmol) and N-hydroxysuccinimide 
(1.9 g, 16.4 mmol) in 50 mL tetrahydrofuran (cooled to -20 °C).  The mixture was 
stirred for 60 min at -20°C, then left at 4 °C overnight.  The precipitated N, N'-dicyclo- 
hexylurea was removed by filtration, the filtrate was evaporated to dryness, and the 
residue was crystallized from THF/2-propanol (1:2, V/V) to yield 4.5 g (7.7 mmol, 
93.0%) of 5. 
0.8 g (2 mmol) of 3 was dissolved in DMSO/dichloromethane (1:1, V/V).  A 
solution of 5 (1.2 g, 2 mmol) in the same solvent was added to the above solution, the 
mixture was stirred at 4 °C for 24 h.  Dichloromethane was evaporated, and the 
precipitate was removed by filtration.  Then 20 mL water was added to the residue. 
 











































































































The resulted suspension was dialyzed against distilled water for 48 h (10-12 KD 
cutoff dialysis membrane) to remove DMSO and 3.  The dialysate was lyophilized to 
yield 1.43 g (1.6 mmol, 80%) of 6, which was a novel compound.  The structure of 6 
was determined by the aids of ESI-MS, 1H NMR, 13C NMR and 2D-NMR spectra7. 
Doxroubicin (DOX) was uptake in conventional liposomes (CL DOX) and 
galactosylated liposomes (incorporated with 10% mol/mol of 6, GalL DOX) in response 
to sulfate ammonium gradients, and the entrapped efficiency was more than 95%6.  The 
liver accumulation and intrahepatic distribution in mice of CL DOX and Gal DOX was 
studied just as Kawakami described3.  Kunming mice were injected with CL DOX or 
GalL DOX through tail vein at a dose of 10 mg /kg, the profile of time course of DOX 
concentration in liver was shown in Figure 1.  GalL DOX was rapidly accumulated to 
the liver (up to 70.29 ±11.66 % of the dose within 1 h).  The amount of GalL DOX in 
liver was significantly higher than that of CL DOX.  Moreover, the results of 
intrahepatic distribution experiment demonstrated that GalL DOX was mainly taken up 
by parenchymal cells (88% of the total hepatic uptake).  These results suggested that 
liposomes containing 6 could be a useful drug delivery carrier for hepatocyte-selective 
targeting. 
 
Figure 1  Liver accumulation of DOX after intravenous injection of GalL DOX (- -) and CL 
DOX (- -). 
 




























Each point represents the mean percentage dose ± SD. (** P<0.05) 
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